Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation

NICE technology appraisals [TA249] Published date:

NICE recommends dabigatran etexilate as a possible treatment to prevent stroke and systemic embolism in people with atrial fibrillation.

Who can have dabigatran etexilate?

You should be able to have dabigatran etexilate if you have a type of atrial fibrillation known as nonvalvular and at least one of the following applies:

  • you have had a stroke, transient ischaemic attack (mini stroke) or embolism in the past
  • your heart pumps less blood around your body than normal
  • you have symptoms of heart failure of New York Heart Association class 2 or above (mild shortness of breath and/or chest pain, and slight limitation during ordinary activity)
  • you are 75 or older
  • you are 65 or older and have diabetes, coronary artery disease or high blood pressure.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommends dabigatran etexilate because its cost is justified by the benefits it provides compared with other treatments available on the NHS.

Get involved